Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

European Journal of Cancer(2025)10.1016/j.ejca.2025.115694Source: DataRank Database

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance) is a research paper published in European Journal of Cancer (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 0.52)OA: hybridTopics (33)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

Bert H. O’Neil ORCID,Sebastian Stintzing ORCID,Fang‐Shu Ou ORCID,Tyler Zemla ORCID,Donna Niedzwiecki ORCID

Live enrichment

PubMed:40803104 PMC:PMC13075548 OpenAlex:https://openalex.org/W4412980453

National Institutes of Health

Grant: U10CA180888

National Institutes of Health

Grant: U10CA180882

National Institutes of Health

Grant: UG1CA180830

National Institutes of Health

Grant: UG1CA233373

National Institutes of Health

Grant: UG1CA233253

National Institutes of Health

Grant: UG1CA233337

National Institutes of Health

Grant: UG1CA233180

National Institutes of Health

Grant: U10CA180821

National Cancer Institute

Genentech

Pfizer

FWCI

0.52

Citation Percentile

0.7%

Citation Trend

2025

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.ejca.2025.115694

publisherhttps://doi.org/10.1016/j.ejca.2025.115694

publisherhttps://api.elsevier.com/content/article/PII:S0959804925004769?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0959804925004769?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40803104

Fields of Study

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsColorectal and Anal Carcinomas

MeSH Terms

BevacizumabCetuximabOxaliplatinProgression-Free SurvivalAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinLeucovorinFemaleFluorouracilHumansMaleMiddle AgedColorectal NeoplasmsTreatment OutcomeChemotherapy, Adjuvant

Keywords

FOLFIRIBevacizumabMedicineCetuximabOxaliplatinOncologyInternal medicineAdjuvantColorectal cancerChemotherapyCancerAdjuvant ChemotherapyFirst-line Therapy

Sustainable Development Goals

SDG 0: Zero hunger